World Health Organization pre-qualifies Indian vaccine for typhoid

Leslie Hanson
January 12, 2018

Global estimates of the typhoid burden range between 11 and 20 million cases and between about 128 000 and 161 000 typhoid deaths annually.

Bharat, which makes vaccines against nine other diseases, including one approved by the World Health Organization for polio, is developing immunisations against Ebola, chikungunya, Zika and non-typhoid strains of Salmonella. "This recommendation paves the way for countries to introduce the vaccine into their immunization programme", Ella said, pointing out that Typbar TCV is the first typhoid conjugate vaccine that has been clinically proven to be administered to children from six months of age to adults and confers long-term protection against typhoid fever.

Hyderabad-based Bharat Biotech would shortly be sending another 2,00,000 doses of its Typbar TCV vaccine to Pakistan's Hyderabad province that has been battling for the past eight months a severe drug resistant version of the disease, which killed hundreds of children. The officials hope that the use of the vaccine will halt the inappropriate use of antibiotics for possible cases of infection and therefore slow the rate of antibiotic resistance.

In October 2017, the Strategic Advisory Group of Experts (SAGE) on immunization, which advices World Health Organization, recommended TCV for routine use in children over 6 months of age in typhoid endemic countries.

The vaccine now costs $1.50 a dose when purchased for developing countries, and the price will drop to $1 or less if donors order more than 100 million doses, said Bharat's chairman, Krishna M. Ella. The highest burden of typhoid is due to salmonella typhi.


Typhoid is an acute illness associated with fever. Typhoid vaccines - alongside safe water, sanitation, and hygiene interventions - are a critical component to reducing the disease's burden in high-risk, endemic areas. Most typhoid cases in the US are from people who have recently traveled internationally.

The single dose vaccine is available for adults and children. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. At Sabin, we believe in the power of vaccines to change the world.

There are two vaccines to prevent typhoid. In October 2017, the Coalition joined forces with the Typhoid Vaccine Acceleration Consortium (TyVAC) to take on typhoid. Now available typhoid vaccines fail to provide long term protection and protection for children below 2 years of age.

The Typhoid Vaccine Acceleration Consortium (TyVAC) is a partnership between the Center for Vaccine Development (CVD) at the University of Maryland School of Medicine, the Oxford Vaccine Group at the University of Oxford, and PATH, an global nonprofit organization.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER